Pentasa Alternatives Compared
| Pentasa (mesalamine) | Entyvio (vedolizumab) | Humira (adalimumab) |
|
|---|
| Pentasa (mesalamine) | Entyvio (vedolizumab) | Humira (adalimumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Ulcerative Colitis - Maintenance, Ulcerative Colitis - Active, Crohn's Disease - Maintenance, Inflammatory Bowel Disease, Ulcerative Colitis, Ulcerative Proctitis. Pentasa may also be... View more |
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Prescription only
Humira is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
Related suggestions Ulcerative Colitis
Crohn's Disease, Maintenance
|
|||||||||||||||||||||||
| More about Pentasa (mesalamine) | More about Entyvio (vedolizumab) | More about Humira (adalimumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Pentasa has an average rating of 7.7 out of 10 from a total of 89 ratings on Drugs.com. 69% of reviewers reported a positive effect, while 10% reported a negative effect. |
Entyvio has an average rating of 6.2 out of 10 from a total of 162 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 28% reported a negative effect. |
Humira has an average rating of 6.4 out of 10 from a total of 698 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 31% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Pentasa side effects |
View all Entyvio side effects |
View all Humira side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Pentasa prices |
View all Entyvio prices |
View all Humira prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other mesalamine brands include: Apriso, Asacol, Asacol HD, Canasa, Canasa Pac, Delzicol, Lialda, Rowasa, Rowasa Sulfite Free, Zaldyon View more | Other vedolizumab brands include: Entyvio Pen | Other adalimumab brands include: Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
10 hours |
600 hours |
480 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category B
No proven risk in humans
Excluding Asacol And Asacol HD
Category C
Risk cannot be ruled out
Asacol And Asacol HD See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 121 drugs are known to interact with Pentasa:
|
A total of 165 drugs are known to interact with Entyvio:
|
A total of 552 drugs are known to interact with Humira:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
May 10, 1993 |
May 20, 2014 |
December 31, 2002 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.